Evidence map›Paper›PMID 19275490›Full record

Trial reportThe Journal of infectious diseases2009

Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy.

Marit G A van Vonderen, Elly A M Hassink, Michiel A van Agtmael, Coen D A Stehouwer, Sven A Danner, Peter Reiss, Yvo Smulders

2 registry-linked trialsAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The Journal of infectious diseases, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01683656 phase4terminatedstarted 2012, after this paper: background citation

ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART

Ran2012Enrolled4Registered outcomes5Posted comparisons0ConditionsAtherosclerosis, HIVArmsNiacin/laropiprant, Placebo
Open the trial in the graph
NCT00122226 phase4unknown statusnot on this map

MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)

TypeinterventionalSponsorAmsterdam UMC, location VUmcRan2003 to 2008Enrolled50ConditionsHIV Infections, HIV-Associated Lipodystrophy SyndromeArmsLopinavir/ritonavir + zidovudine + lamivudine, Lopinavir/ritonavir + nevirapine
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Endothelial Dysfunction as a Primary Consequence of SARS-CoV-2 Infection.Advances in experimental medicine and biology · 2021
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marit G A van VonderenDepartment of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands. M.vVonderen@vumc.nl
Elly A M Hassink
Michiel A van Agtmael
Coen D A Stehouwer
Sven A Danner
Peter Reiss
Yvo Smulders

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe risk of cardiovascular disease in human immunodeficiency virus (HIV)-infected patients is an increasing concern. We studied the changes in vascular properties after the initiation of combination antiretroviral therapy (cART) as well as the contribution of different drug classes.

methodscART-naive men were randomized to receive either lopinavir/ritonavir (LPV/r) plus zidovudine/lamivudine (ZDV/3TC) (n = 19) or LPV/r plus nevirapine (NVP) (n = 18). Carotid artery intima-media thickness (C-IMT), arterial stiffness (distensibility coefficients [DCs] and compliance coefficients [CCs] of the carotid, femoral, and brachial arteries; carotid elastic modulus; and augmentation index), and markers of endothelial function (soluble vascular cell adhesion molecule [sVCAM]-1, intercellular adhesion molecule [sICAM]-1, plasma von Willebrand factor (vWF) antigen, and plasminogen activator inhibitor-1 antigen) and inflammation (high-sensitivity C-reactive protein) were measured before the initiation of cART and after 3, 12, and 24 months of cART.

resultsC-IMT increased by 0.061 +/- 0.016 mm (P < .001) in the ZDV/3TC/LPV/r arm and by 0.044 +/- 0.018 mm (P = .012) in the NVP/LPV/r arm (data are estimated means +/- SEs). Femoral artery DC (-1.66 +/- 0.78 x 10(-3)/kPa [P = .035]) and CC (-0.11 +/- 0.053 mm(2)/kPa [P = .43]) decreased in the ZDV/3TC/LPV/r arm and femoral DC decreased in the NVP/LPV/r arm (-1.72 +/- 0.85 x 10(-3)/kPa [P = .046]), with no significant difference in C-IMT or arterial stiffness between arms. sVCAM-1, sICAM-1, and vWF levels decreased significantly in both groups.

conclusionC-IMT and femoral artery stiffness increased after the initiation of cART, whereas several markers of endothelial function improved, regardless of the composition of cART. Trial registration. ClinicalTrials.gov identifier: NCT00122226 .

Indexed as

AdolescentAdultAgedAnti-HIV AgentsBody CompositionBrachial ArteryCardiovascular DiseasesCarotid ArteriesComplianceEndothelium, VascularFemoral ArteryHIV InfectionsHumansMaleMiddle AgedTunica IntimaAnti-HIV Agents

Identifiers

PMID19275490

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.